Anito-cel (anitocabtagene autoleucel)
Gilead Sciences (Arcellx) (GILD)
Decision dateDec 23, 2026
38 days away
Marketer take
A new CAR-T entrant in late-line myeloma, where treatment-center onboarding and referral pathways matter more than broad HCP reach.
- Sponsor company
- Gilead Sciences (Arcellx) (GILD)
- Indication
- Relapsed/refractory multiple myeloma, 4th line and later
- Therapeutic area
- Oncology, Hematology
- Event
- PDUFA target action date
- Date
- Dec 23, 2026
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?